Testosterone Cypionate Injection, USP, 200 mg/mL, 1 mL Single-dose vial per carton, Rx only, Dist...
FDA Drug Recall #D-1154-2022 — Class II — June 10, 2022
Recall Summary
| Recall Number | D-1154-2022 |
| Classification | Class II — Moderate risk |
| Date Initiated | June 10, 2022 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | SUN PHARMACEUTICAL INDUSTRIES INC |
| Location | Princeton, NJ |
| Product Type | Drugs |
| Quantity | 47,500 vials |
Product Description
Testosterone Cypionate Injection, USP, 200 mg/mL, 1 mL Single-dose vial per carton, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512; Manufactured by: Sun Pharmaceutical Industries Ltd., Halol-Baroda Highway, Halol-389 350, Gujarat, India, NDC 62756-015-40.
Reason for Recall
Lack of Assurance of Sterility: Manufacturing deviation which was reported due to a microbial excursion
Distribution Pattern
Nationwide within the United States
Lot / Code Information
Lot: HAC3427A, EXP Date: 08/2023
Other Recalls from SUN PHARMACEUTICAL INDUSTRIES INC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0342-2026 | Class II | Diclofenac Sodium, Topical Gel, 3%, 100 g tube,... | Jan 27, 2026 |
| D-0256-2026 | Class III | Fluocinolone Acetonide Solution Topical Solutio... | Dec 30, 2025 |
| D-0257-2026 | Class III | Clindamycin Phosphate USP, 1% (10 mg/mL), Topic... | Nov 26, 2025 |
| D-0149-2026 | Class II | Lisdexamfetamine Dimesylate Capsules, 60 mg, CI... | Oct 28, 2025 |
| D-0150-2026 | Class II | Lisdexamfetamine Dimesylate Capsules, 70 mg, CI... | Oct 28, 2025 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.